follow us
disclaim warranti liabil
due number sourc inform servic acquisdata pti ltd servic obtain
inher hazard electron distribut may delay omiss inaccuraci inform
servic acquisdata pti ltd affili agent sale repres distributor licensor
warrant accuraci complet current merchant abil fit particular purpos
inform servic avail acquisdata pti ltd servic event acquisdata pti ltd
affili agent sale repres distributor licensor liabl license anyon els loss
injuri caus whole part conting beyond control procur compil interpret edit write
report deliv inform servic acquisdata pti ltd servic event acquisdata
pti ltd affili agent sale repres distributor licensor liabl license anyon els
decis made action taken license relianc upon inform servic consequenti
special similar damag even advis possibl damag license agre liabil
acquisdata pti ltd affili agent sale repres distributor licensor aris kind
legal claim whether contract tort otherwis way connect acquisdata pti ltd servic shall
exceed amount license paid use acquisdata pti ltd servic twelv month immedi
preced event give rise claim
 product sale billion
 dilut ep per share
 non-gaap dilut ep per share
foster citi calif -- busi -- may inc announc today
result oper first quarter end march financi result follow repres year-
over-year comparison first quarter first quarter total revenu billion
compar billion net incom billion per dilut share compar
billion per dilut share non-gaap net incom billion per dilut share
compar billion per dilut share
royalti contract revenu
net incom attribut gilead
total product sale first quarter billion compar billion period
product sale first quarter billion unit state million europ
million locat product sale first quarter billion unit state billion
europ million locat
compens expens fair valu adjust equiti secur discret tax charg benefit
associ chang tax relat law guidelin reconcili non- financi
inform provid tabl page
hiv product saleswer billion first quarter compar billion period
increas primarili driven higher sale volum result continu uptak biktarvi bictegravir
chronic hepat viru hcv product sale million first quarter compar billion
period declin primarili due lower patient start competit dynam
includ declin price medicar
yescarta axicabtagen ciloleucel approv unit state octob europ august
gener million sale first quarter compar million period
increas driven increas number therapi provid patient
product sale includ product gilead chronic hepat viru hbv cardiovascular oncolog
categori inclus vemlidi tenofovir alafenamid mg viread tenofovir disoproxil fumar
mg letairi ambrisentan mg mg ranexa ranolazin mg mg zydelig idelalisib
mg ambisom amphotericin liposom inject mg/vial million first quarter
compar million period decreas primarili due expect declin
ranexa sale gener entri first quarter
research develop expens
sell gener administr expens sg
first quarter compar period
 expens increas primarili due up-front collabor expens higher invest support gilead
cell therapi program partial off-set lower stock-bas compens expens stock-bas compens
expens higher first quarter follow acquisit kite pharma inc kite
non-gaap expens increas primarili due higher invest support gilead cell therapi program
sg expens increas primarili due higher promot expens unit state expens
associ expans gilead product europ japan partial off-set lower stock-bas
compens expens stock-bas compens expens higher first quarter follow
acquisit kite
non-gaap sg expens increas primarili due higher promot expens unit state
expens associ expans gilead product europ japan
effect tax rate non-gaap effect tax rate first quarter compar
period respect decreas primarili due favor
settlement tax author full year gilead reiter effect tax rate guidanc non-
effect tax rate guidanc rang respect
equival market debt secur
march gilead billion cash cash equival market debt secur compar
billion decemb first quarter gilead gener billion oper
cash flow repaid million debt paid cash dividend million util million stock
gilead reiter full year guidanc initi provid februari guidanc product sale
reflect anticip entri gener version letairi ranexa unit state full year impact
gener product contain tenofovir disoproxil fumar certain european countri
million except percentag per share amount
dilut ep impact acquisition-rel up-front collabor stock-bas compens
corpor highlight includ announc
hepconnect five-year multi-million dollar initi aim address sharp increas chronic hcv
infect fuel nation opioid crisi partnership harm reduct coalit local
organ initi support evidence-bas solut meet need peopl affect
opioid crisi indiana kentucki north carolina tennesse west virginia
departur alessandro riva md execut vice presid oncolog therapeut left gilead becom
ceo anoth pharmaceut compani
gilead hiv posit initi provid million grant organ unit
state effort aim enhanc live individu age hiv focus three prioriti area
improv care coordin increas resourc better well-b educ inform polici
impact peopl live age hiv
product pipelin updat includ announc
week result finch on-going random double-blind placebo- active-control phase studi
filgotinib investig oral select inhibitor adult moderately-to-sever activ rheumatoid
arthriti ra finch evalu filgotinib versu adalimumab placebo stabl background dose
methotrex patient prior inadequ respons methotrex studi achiev primari endpoint
dose filgotinib proport patient achiev american colleg rheumatolog respons
compar placebo week
week result finch on-going random double-blind active-control phase studi filgotinib
adult moderately-to-sever activ ra finch evalu filgotinib combin methotrex
monotherapi mtx-nave patient studi achiev primari endpoint proport patient
achiev respons week proport patient achiev primari endpoint
respons week significantli higher filgotinib mg plu filgotinib mg plu
compar alon
interim safeti inform four studi filgotinib treatment ra data includ week result
on-going phase finch trial updat week safeti data phase darwin long-
term extens studi patient ra
hiv liver diseas program
data gilead research develop program nonalcohol steatohepat nash primari scleros
cholang viral hepat present intern liver congress vienna austria data
reflect gilead on-going focu commit advanc research patient care across field liver
approv japan ministri labour welfar mhlw biktarvi treatment infect
present data confer retrovirus opportunist infect includ
result discov trial two-year phase random control double-blind studi evalu
safeti efficaci investig use once-daili descovi emtricitabin mg/tenofovir alafenamid
mg hiv pre-exposur prophylaxi prep compar truvada emtricitabin mg tenofovir
disoproxil fumar mg prep men sex men transgend women risk sexual
acquir hiv infect trial descovi achiev primari efficaci endpoint demonstr non-inferior
truvada statist signific advantag respect bone renal laboratori paramet observ
particip receiv descovi compar receiv truvada
result phase studi week evalu efficaci safeti biktarvi virolog suppress
adolesc children least year age live hiv
result two studi evalu resist profil biktarvi virolog suppress adult switch
dolutegravir/abacavir/lamivudin boost proteas inhibitor-bas regimen treatment
result two studi support develop investig novel select first-in-
class inhibitor capsid function potenti futur use part long-act hiv combin therapi interim
blind data phase studi healthi trial particip demonstr singl dose
mg administ subcutan achiev sustain concentr level well-toler
result phase random double-blind placebo-control studi evalu safeti
efficaci selonsertib investig once-daili oral inhibitor apoptosi signal-regul kinas patient
compens cirrhosi due nash meet pre-specifi week primari endpoint
stage histolog improv fibrosi without worsen nash
approv japan mhlw epclusa sofosbuvir mg/velpatasvir mg adult chronic hcv
infect decompens cirrhosi patient chronic hcv infect without cirrhosi
compens cirrhosi prior treatment direct-act antivir therapi
licens agreement collabor agreement yuhan corpor co-develop novel therapeut
candid treatment advanc fibrosi due nash
inc research-bas biopharmaceut compani discov develop commerci
innov medicin area unmet medic need compani strive transform simplifi care peopl
life-threaten ill around world gilead oper countri world-wide
headquart foster citi california
acquisdata proud host leagu estim want opportun win free
subscript join acquisdata media telecommun leagu
gilead research-bas biopharmaceut compani discov develop commerci innov medicin
area unmet medic need gilead product pipelin investig drug includ treatment
hiv/aid liver diseas seriou respiratori cardiovascular condit cancer inflamm market
product includ number categori first includ first complet treatment regimen hiv infect
avail once-daili singl pill first oral antiretrovir pill avail reduc risk acquir hiv
infect certain high-risk adult
acquisdata date busi intellig report cover develop world
report vast archiv corpor document list compani around world
global biopharmaceut compani develop deliv therapi patient
sever life-threaten diseas also ultra-rar alexion first commerci product soliri
eculizumab world first approv termin complement inhibitor today soliri approv nearli
countri treatment patient paroxysm nocturn hemoglobinuria pnh us european
union japan countri treatment patient atyp hemolyt urem syndrom ahu
discov develop manufactur deliv innov human therapeut use tool like advanc
human genet compani focus area high unmet medic need leverag biolog
manufactur expertis strive solut improv health outcom grown world
largest independ biotechnolog compani reach million patient around world develop
pipelin medicin breakaway potenti
biogen idec discov develop deliv patient world-wide innov therapi treatment
neurodegen diseas hemophilia autoimmun disord found world oldest
independ biotechnolog compani fortun compani billion annual revenu
biomarin found develop commerci innov biopharmaceut seriou diseas
medic condit compani four approv product naglazym galsulfas product wholli
develop commerci biomarin aldurazym laronidas develop joint ventur
genzym corpor kuvan sapropterin dihydrochlorid tablet develop partnership merck serono
divis merck kgaa darmstadt germani firdaps amifampridin approv
european commiss treatment lambert eaton myasthen syndrom
celgen global biopharmaceut compani discov develop commerci product treatment
cancer sever immun inflammatori condit clinic trial major medic
center use compound celgen
regeneron lead scienc technolog compani deliv life-transform medicin seriou diseas
found physician-scientist nearli year ago compani science-driven approach result four
fda-approv medicin numer product candid rang diseas includ ophthalmolog
rheumatoid arthriti atop dermat asthma pain cancer infecti diseas
seattl genet biotechnolog compani focus develop commerci innov empow
antibody-bas therapi treatment cancer industri leader antibody-drug conjug adc
technolog design har target abil monoclon antibodi deliv cell-kil agent directli
cancer cell adc intend spare non-target cell thu reduc mani toxic effect tradit
chemotherapi potenti enhanc antitumor activ addit one market product advanc
deep product pipelin address signific unmet medic need
seattl genet found headquart bothel washington suburb seattl
compani complet initi public offer march trade nasdaq stock market
symbol compani employe passion help peopl live cancer
shire lead global biotechnolog compani focus serv peopl rare diseas highli
special condit strive develop best-in-class product mani avail
storag disord gastrointestin intern medicin endocrin hereditari angioedema grow
franchis oncolog
vertex global biotechnolog compani discov develop commerci innov new medicin
treat seriou diseas found cambridg vertex today research develop site
commerci offic us canada europ australia four year row scienc magazin name
vertex one top employ life scienc
unit state largest market biopharmaceut account around third global market
world leader biopharmaceut accord pharmaceut research manufactur
associ phrma firm conduct half world pharmaceut billion hold
intellectu properti right new medicin overal econom impact biopharmaceut industri
 economi substanti industri account trillion econom output repres
percent total output total econom impact includ billion revenu
biopharmaceut busi billion supplier worker spend
peopl work biopharmaceut industri unit state across broad rang
occup includ scientif research technic support manufactur directli indirectli industri
support million job across unit state industri requir highly-skil educ
workforc administr level includ ph scientist third job sector key
unit state one world support domest environ develop
commerci pharmaceut minim market barrier strength includ intellectu properti
system reward innov patent data protect science-bas regulatori system
consid rigor world largest scientif research base foster academ institut
decad govern research fund robust capit market unit state attract major
global ventur capit invest start-up biopharmaceut enterpris
acquisdata date busi intellig report cover develop world
report vast archiv corpor document list compani around world
